CWY

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Selective serotonin reuptake inhibitor, Obesity, CWY, Patent, Central nervous system, SSRI, Patient, DSM-IV codes, Mental health, Anxiety, Therapy, USD, Pharmaceutical industry

Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”).
  • Under our collaboration with SciSparc, we believe that our proprietary drugs can positively impact patients dealing with various forms of depression including treatment resistant depression," stated Dr. Adi Zuloff-Shani, CEO of Clearmind.
  • "We further believe that we have a tremendous opportunity to develop viable alternatives to the current SSRIs for individuals living with depression.

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Obesity, CWY, Central nervous system, DSM-IV codes, Anxiety, Patent, Therapy, Disorder, USD, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.

Key Points: 
  • TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.
  • The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • According to the ResearchAndMarkets.com , the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s CannAmide™with Clearmind’s MEAI compound for the treatment of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Retrieved on: 
Tuesday, March 19, 2024
Alcoholism, CWY, Binge drinking, MEAI, IP, Patent, Therapy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.

Key Points: 
  • The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application.
  • This latest patent builds upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.
  • The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.
  • Clearmind’s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024
Dopamine, NET, Reward, Sheba Medical Center, CWY, Psychiatry, Serotonin, Patient, Research, MEAI, Alcoholism, Clinical trial, DAT, Safety, Norepinephrine, Yale school, Therapy, Ministry, Pharmaceutical industry

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Retrieved on: 
Wednesday, March 13, 2024
Therapy, CWY

The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ").

Key Points: 
  • The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ").
  • The common shares will continue to trade on the NASDAQ under the symbol CMND.
  • Following delisting from the CSE, Clearmind’s shareholders can trade their common shares through their brokers on NASDAQ.
  • Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade Clearmind’s shares on the NASDAQ.

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Central nervous system, TEL, Obesity, Ketamine, Patent, Ibogaine, PCT, Patent Cooperation Treaty, MDMA, PEA, CWY, Disorder, DSM-IV codes, Pharmaceutical industry

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
  • In addition, seven applications were filed under the PCT.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Central nervous system, DMT, LSD, TEL, Patent, Patent Cooperation Treaty, Psilocybin, PEA, CWY, Disorder, Lysergic acid diethylamide

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
  • "We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler.
  • "We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Central nervous system, DMT, LSD, PCT, Patent Cooperation Treaty, Psilocybin, PEA, Patent, CWY, IP, Lysergic acid diethylamide, Research, Pharmaceutical industry

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.
  • "Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry.
  • The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio.
  • The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Retrieved on: 
Monday, February 5, 2024
Binge drinking, Therapy, CWY, Alcoholism, MEAI, IP, Patent, Pharmaceutical industry

The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.

Key Points: 
  • The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.
  • "We are proud to receive once again recognition of our innovative treatment for binge behaviors.
  • “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders.
  • Clearmind’s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.